#USA #Intensity Therapeutics #Shelton #INVINCIBLE Study #Q3 2026

Intensity Therapeutics Provides Q3 2026 Business Update

Intensity Therapeutics, Inc. (NASDAQ: INTS) shared its latest financial outcomes and significant developments in a conference call on November 5, 2026. Focused on groundbreaking cancer therapies, the company is making strides in its clinical trials, notably in treating soft tissue sarcomas and triple-negative breast cancer (TNBC) using novel intratumoral therapy, INT230-6.

Key Highlights from Q3 2026

The company reported a cash balance of $8.5 million as of September 30, 2026, alongside encouraging signs as patient recruitment resumed in limited areas across the U.S. for two ongoing studies—the INVINCIBLE-3 and INVINCIBLE-4 trials. These studies investigate the effectiveness of INT230-6 against specific cancer types by directly injecting the therapeutic agent into the tumors, aiming to enhance immune response and tumor elimination.

INVINCIBLE-3 Study Update

The INVINCIBLE-3 Study is a Phase 3 clinical trial comparing INT230-6 as a monotherapy to standard-of-care treatments for patients with certain soft tissue sarcoma subtypes. After a pause in March 2025 due to funding issues, the study reinitiated patient enrollment in Q3 2026 under an FDA-reviewed amended protocol. This renewed effort follows feedback from leading sarcoma researchers and aims to enhance trial protocols based on prior learnings.

Management expressed optimism about the ongoing recruitment and activation of new study sites. The company is also in the process of restarting participation in the EU and Canada, further expanding its patient recruitment potential.

INVINCIBLE-4 Study Overview

In March 2025, enrollment in the INVINCIBLE-4 Study was momentarily halted to address skin irritation side effects experienced by patients receiving INT230-6 treatment. After a successful amendment to the dosing regimen approved by regulatory bodies in Switzerland and France, enrollment has recommenced with the goal of completing the study by the end of 2027. Initial data from this study has shown promising results, including a 71% pathological complete response (pCR) rate in patients receiving INT230-6, compared to only a 42% rate in those receiving standard of care, signaling significant potential benefits from this innovative treatment.

Financial Performance

Intensity's research and development expenses surged to $2.4 million in Q3 2026, up from $1.6 million in Q3 2025, reflecting the resumption of clinical trial activities. General and administrative costs held steady at $1.2 million, with a net loss reported at $3.5 million for the quarter, compared to a loss of $2.7 million the previous year. Despite these financial challenges, the company secured an additional $1.6 million in proceeds from its $60 million at-the-market facility, demonstrating ongoing support from investors.

Looking Forward

Lewis H. Bender, President and CEO, emphasized the excitement surrounding patient recruitment in both trials and the positive reception of protocol adjustments from investigators. The focus remains on strengthening patient enrollment while ensuring the safety and efficacy of INT230-6. With vital meetings held at ESMO, there are plans for further collaboration and development opportunities to bolster the company’s research.

Concluding Thoughts

Intensity Therapeutics is positioned to redefine cancer treatment paradigms through its innovative approach to intratumoral therapy. By actively pursuing clinical advancements and financial sustainability, the company aims to bring effective treatment options for aggressive cancers like TNBC and soft tissue sarcomas to more patients, transforming cancer management into a more manageable condition. For continuous updates and detailed insights, investors and stakeholders are encouraged to follow their progress in the coming months.